

The future of kidney care is patient-centric

Treating kidney disease is complex and costly, with US Medicare alone spending **\$2B a week**.

Innovative, venture-backed value-based kidney care providers are seizing the initiative with 10% of patients now covered and **market share growing rapidly**.

Providers and patients need better data and tools to **reduce health risks and enable new treatments**.

Yet personalized monitoring of many blood markers is currently impossible

Treatment currently relies upon venous blood tests, with patients traveling from their homes to clinics, knowing that results will not be available for hours or days.

This makes personalization using real-time data impossible and leaves patients disempowered.

Company raising finance to achieve key commercial milestones

Spinout from University of Cambridge

Novel blood sensing IP including three patent families

Poised to transform the standard of care via market entry within two years

Previous work with Fresenius in the USA

In advanced discussions with US FDA with clear regulatory pathway

Near-term commercial and clinical partnership opportunities

Kalium enables monitoring by clinicians and patients anywhere, any time



We have developed health monitoring technology that is rapid, accurate and suitable for use by physicians or patients themselves. Using a single drop of fingertip blood the Kalium handheld monitor provides rapid results for timely clinical action.

Everything is digitally connected to enable physicians to better optimise treatments and data is clearly visualized on our smartphone app to allow patients, for the first time, to monitor key risks and access AI to help them manage their health and lifestyle.

Our first target is blood potassium – a silent killer

High blood potassium (hyperkalemia) causes death without warning, and common blood pressure medications increase this risk. Low blood potassium (hypokalemia) is also life-threatening.

Potassium monitoring will save lives by providing results in seconds, not days, and enabling dynamic adjustment of life-saving medications with their effect on potassium safely monitored.

Potassium monitoring addresses a multi-billion cost burden

In the USA, high potassium more than doubles the cost of care from **\$15,000 to \$34,000** for an estimated 1m Medicare patients. This pattern is seen worldwide as treating high potassium leads to additional hospital admissions. We are addressing this huge economic opportunity by making potassium data accessible and actionable, to prevent disease escalation and avoid unplanned costs. Value-based kidney care organisation provide opportunities for fast market entry with established distribution channels and incentive for innovation.

Company building for long-term growth

Founded by domain experts, Kalium Health is led by experienced company-builders and backed by investors including Cambridge Enterprise, Martlet Capital, Kidney Research UK and Jonathan Milner. Ranndy Kellogg, President and CEO of Omron Healthcare and Director of AliveCor, has recently joined the Board to support our commercial strategy focused on rapid market entry.

We are strong proponents of Environment, Social and Governance initiatives and our strategy aligns with UN Sustainable Development Goals 3 (good health and well-being) and 9 (industry, innovation and infrastructure).



To request further information email investors@kaliumhealth.com or see www.kaliumhealth.com/investors